Immunocore HoldingsIMCR -3.56%76 PS Ratio is 3.95 as of Jul. 11, 2026, which is 69% below its 10-year median of 12.74. GuruFocus rates IMCR with a GF Score™ of 76/100 and a GF Value™ of $46.19 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 930 Biotechnology companies, Immunocore Holdings ranks better than 71.94% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Immunocore Holdings's share price is $31.95.
Immunocore Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $8.09. Hence, Immunocore Holdings's PS Ratio for today is 3.95.
The historical rank and industry rank for Immunocore Holdings's PS Ratio or its related term are showing as below:
IMCR'
s PS Ratio Range Over the Past 10 Years
Min: 3.47 Med: 12.74 Max: 76.67
Current: 4
During the past 8 years, Immunocore Holdings's highest PS Ratio was 76.67. The lowest was 3.47. And the median was 12.74.
IMCR's PS Ratio is ranked better than 71.94% of 930
companies
in the Biotechnology industry
Industry Median: 9.515
vs IMCR: 4.00
Immunocore Holdings PLC revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Immunocore Holdings was 24.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 27.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 54.90% per year.
During the past 8 years, Immunocore Holdings's highest 3-Year average Revenue per Share Growth Rate was 1462.40% per year. The lowest was 27.70% per year. And the median was 93.30% per year.
Back to Basics: PS Ratio
Immunocore Holdings (NAS:IMCR) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Immunocore Holdings PS Ratio Related Terms
Immunocore Holdings PS Ratio Historical Data
* Premium members only.
The historical data trend for Immunocore Holdings's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Immunocore Holdings's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immunocore Holdings PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immunocore Holdings's PS Ratio distribution charts can be found below:
* The bar in red indicates where Immunocore Holdings's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Immunocore Holdings's Share Price of today is $31.95. Immunocore Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.09.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Immunocore Holdings (IMCR) has a PS Ratio of 3.95 as of Jul. 11, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Immunocore Holdings and its competitors. This is 69% below median its historical median of 12.74. Over the past decade, Immunocore Holdings' PS Ratio has ranged from 3.47 to 76.67. According to the industry distribution chart, Immunocore Holdings ranks #261 out of 930 companies in the Biotechnology industry, placing it in the top 28.1%.
Is Immunocore Holdings' PS Ratio too high?
Immunocore Holdings' current PS Ratio of 3.95 is 69% below median its 10-year median of 12.74. Over the past 10 years, this metric has ranged from a low of 3.47 to a high of 76.67. The Biotechnology industry median PS Ratio is 9.52. Immunocore Holdings' value of 3.95 is 58.5% below this industry median. Based on the distribution chart, Immunocore Holdings ranks #261 out of 930 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Immunocore Holdings has a GF Score™ of 76/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Immunocore Holdings' PS Ratio compare to MAZE and DMRA?
According to the Biotechnology industry distribution chart, Immunocore Holdings ranks #261 out of 930 companies for PS Ratio. This puts Immunocore Holdings in the upper half of its industry. The industry median PS Ratio is 9.52. Immunocore Holdings' value of 3.95 is 58.5% below this benchmark. Historically, Immunocore Holdings' own PS Ratio has ranged from 3.47 to 76.67 over the past decade. While the company's 10-year median is 12.74 vs. the industry median of 9.52, Immunocore Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.52, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Immunocore Holdings's current PS Ratio of 3.95 is 58.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Immunocore Holdings and its competitors. For the Biotechnology industry, the median PS Ratio is 9.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immunocore Holdings's current PS Ratio is 3.95, which is 69% below median its own 10-year median of 12.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunocore Holdings stock overvalued right now?
Based on GuruFocus' analysis, Immunocore Holdings (IMCR) is currently considered Possible Value Trap. The stock's GF Value™ is $46.19, compared to a current price of $31.95 — trading 30.8% below its estimated fair value. The current PS Ratio is 3.95, which is 69% below median its 10-year median of 12.74 and 58.5% below the Biotechnology industry median of 9.52. Immunocore Holdings' overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Immunocore Holdings (IMCR), the current PS Ratio is 3.95 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immunocore Holdings (IMCR) Overvalued in 2026?
Based on GuruFocus' analysis, Immunocore Holdings stock appears to be undervalued.
The current stock price of $31.95 is trading 30.8% below its estimated GF Value™ of $46.19.
GuruFocus considers Immunocore Holdings to be Possible Value Trap.
Key valuation signals for IMCR:
PS Ratio: 3.95 (69% below median its 10-year median of 12.74)
GF Value™: $46.19 vs. price of $31.95 (30.8% below fair value)
Industry Position: 58.5% below the Biotechnology median (#261 of 930)
No single metric tells the full story. See the IMCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
76GF Score
Get the complete analysis for IMCR
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMCR has been successfully added to your 
